Search

Your search keyword '"Walewski, Jan"' showing total 19 results

Search Constraints

Start Over You searched for: Author "Walewski, Jan" Remove constraint Author: "Walewski, Jan" Topic hodgkin disease Remove constraint Topic: hodgkin disease
19 results on '"Walewski, Jan"'

Search Results

1. New molecular targets in Hodgkin and Reed-Sternberg cells.

2. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial.

3. Peripheral Blood Cells from Patients with Hodgkin's and Diffuse Large B Cell Lymphomas May Be a Better Source of Candidate Diagnostic miRNAs Than Circulating miRNAs.

4. Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy.

5. Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective.

6. Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study.

7. Resminostat in patients with relapsed or refractory Hodgkin lymphoma: results of the phase II SAPHIRE study.

8. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse.

9. Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy.

10. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.

11. Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma.

12. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.

13. Treatment strategy based on gemcitabine-containing salvage chemotherapy used with intent to proceed to second stem cell transplant for patients with Hodgkin lymphoma relapsing after a prior autologous transplant.

14. Discriminant analysis involving serum cytokine levels and prediction of the response to therapy of patients with Hodgkin lymphoma.

15. Serum macrophage colony-stimulating factor (M-CSF) in patients with Hodgkin lymphoma.

16. CHOP-21 for unfavorable Hodgkin's lymphoma. An exploratory study.

17. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.

18. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519).

19. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma

Catalog

Books, media, physical & digital resources